Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

18.37 +1.12 (+6.49%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2025 Add to My Watchlist

Price and Volume

Volume	4,313,580
Open	17.39
Bid (Size)	18.33 (1,200)
Ask (Size)	18.62 (100)
Prev. Close	17.25
Today's Range	17.32 - 19.05
52wk Range	15.55 - 36.91
Shares Outstanding	97,381,774
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Don't Buy Summit Therapeutics Until This Big Thing Happen ↗

December 03, 2025

This biotech company is rolling the dice with a planned regulatory submission.

Via The Motley Fool

2 Monster Stocks in the Making to Buy and Hold ↗

December 02, 2025

There's still time to get in on these rising stars.

Via The Motley Fool

Performance

YTD	+0.1%	+0.1%
1 Month	+0.8%	+0.8%
3 Month	-21.9%	-21.9%
6 Month	-6.1%	-6.1%
1 Year	+3.4%	+3.4%

More News

Summit SMMT Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

November 07, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Stock Sparks Retail Buzz After Ivonescimab Combo Cuts Cancer Progression Risk By 40% ↗

October 19, 2025

Via Stocktwits

An Overview of Summit Therapeutics's Earnings ↗

October 17, 2025

Via Benzinga

Summit Therapeutics to Present at Upcoming Investor Conferences

November 04, 2025

From Summit Therapeutics

Via Business Wire

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

October 31, 2025

From Summit Therapeutics

Via Business Wire

Alpha Buying: When Insiders Buy Big & Why It Works in Every Market ↗

October 30, 2025

Via Benzinga

Why Wall Street Is Backing These 3 Comeback Stocks ↗

October 28, 2025

Via MarketBeat

1 Monster Stock in the Making to Buy and Hold ↗

October 27, 2025

Via The Motley Fool

Summit Therapeutics: A Risky Bet in the Biotech Arena? ↗

October 24, 2025

Via The Motley Fool

Summit Therapeutics Raises $500 Million in Private Placement

October 22, 2025

From Summit Therapeutics

Via Business Wire

What's Going On With Summit Therapeutics Stock On Monday? ↗

October 20, 2025

Via Benzinga

Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More ↗

October 20, 2025

Via Benzinga

Summit Therapeutics Inc (NASDAQ:SMMT) Reports Wider-Than-Expected Q3 2025 Loss ↗

October 20, 2025

Via Chartmill

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

October 20, 2025

From Summit Therapeutics

Via Business Wire

Earnings Scheduled For October 20, 2025 ↗

October 20, 2025

Via Benzinga

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

October 19, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

October 17, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

October 15, 2025

From Summit Therapeutics

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

October 08, 2025

Via Benzinga

1 Monster Stock in the Making to Buy and Hold ↗

October 05, 2025

Via The Motley Fool

Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence ↗

October 01, 2025

Via Benzinga

Intel, Marvell, Electronic Arts Are Among The Top 10 Large-Cap Gainers Last Week (Sep. 22 - Sep. 26): Are The Others In Your Portfolio? ↗

September 28, 2025

Via Benzinga

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?

Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Summit Therapeutics Inc. - Common Stock trade on?

Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?

The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market

What is the current price of Summit Therapeutics Inc. - Common Stock?

The current price of Summit Therapeutics Inc. - Common Stock is 18.37

When was Summit Therapeutics Inc. - Common Stock last traded?

The last trade of Summit Therapeutics Inc. - Common Stock was at 12/03/25 04:00 PM ET

What is the market capitalization of Summit Therapeutics Inc. - Common Stock?

The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.79B

How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?

Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.